← stocks-llm New chat

COHERUS ONCOLOGY INC (CHRS) — insider trading

Health Care · NASDAQ

COHERUS ONCOLOGY INC (CHRS) has 49 reported SEC Form 4 insider transactions in our data (latest 2026-06-05).

Recent Form 4 transactions

DateInsiderRoleTypeSharesPriceValueFiling
2026-06-05 Newton Charles W. Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 Newton Charles W. Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-06-05 Wahlstrom Mats Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 Wahlstrom Mats Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-06-05 O'Donnell-Tormey Jill Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 O'Donnell-Tormey Jill Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-06-05 Ryan Michael Lee Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 Ryan Michael Lee Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-06-05 Newcomer Lee Nisley Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 Newcomer Lee Nisley Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-06-05 Karachun Rita A Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 Karachun Rita A Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-06-05 Satvat Ali J. Director Grant / award / vesting (derivative) 60,000 $0.00 $0 Form 4
2026-06-05 Satvat Ali J. Director Grant / award / vesting 30,000 $0.00 $0 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 225,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 402,500 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 402,500 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 125,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 500,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 500,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 450,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 400,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 200,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 225,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 402,500 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 402,500 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 125,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 500,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 500,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 450,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 400,000 Form 4
2026-05-29 Lanfear Dennis M Director, Officer (President & CEO) Disposition to the issuer (derivative) 200,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 30,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 25,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 25,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 15,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 25,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 100,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Disposition to the issuer (derivative) 30,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Disposition to the issuer (derivative) 25,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Disposition to the issuer (derivative) 25,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Disposition to the issuer (derivative) 15,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Disposition to the issuer (derivative) 25,000 Form 4
2026-05-29 McMichael Bryan J Officer (Chief Financial Officer) Disposition to the issuer (derivative) 100,000 Form 4
2026-01-23 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting (derivative) 750,000 $0.00 $0 Form 4
2026-01-23 Lanfear Dennis M Director, Officer (President & CEO) Grant / award / vesting 375,000 $0.00 $0 Form 4
2026-01-22 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting (derivative) 225,000 $0.00 $0 Form 4
2026-01-22 McMichael Bryan J Officer (Chief Financial Officer) Grant / award / vesting 112,500 $0.00 $0 Form 4
2026-01-20 McMichael Bryan J Officer (Chief Financial Officer) Shares withheld for taxes / exercise cost 1,715 $1.55 $2.7K Form 4

Ask the chat about CHRS's insider activity →

Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.

Source: SEC EDGAR Form 3/4/5. See the full company profile: COHERUS ONCOLOGY INC (CHRS).

Last updated 2026-06-05 (most recent filing date).

Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.